Abstract
Post transplant infusion of donor-type natural killer (NK) cells has been shown to have an anti-leukemia-enhancing effect without evoking GVHD in murine hematopoietic cell transplantation (HCT) models. Here, we tested 14 patients (age, 23–65 years), 12 with acute leukemia and 2 with myelodysplastic syndrome, who underwent HLA-mismatched HCT and subsequently received donor NK cell infusions. Cell donors (age, 16–51 years), comprising seven siblings, five offspring, and two mothers of the patients, underwent growth factor-mobilized leukapheresis for 3–5 days. Cells collected on the first 2–4 days were used for HCT, whereas those collected on the last day were CD34 selected by magnetic-activated cell sorting (median, 2.22 × 106 cells/kg; range, 0.29–5.66). Donor NK cells were generated from the CD34+ cells by ex vivo cell culture over a 6-week period (median, 9.28 × 106 cells/kg; range, 0.33–24.50; CD122/CD56+ 64%; CD3+ 1.0%; and viability 88%). There were no signs of acute toxicity in patients infused with these cells 6–7 weeks post transplant. Overall, one and five patients developed acute and chronic GVHD during post transplant period, respectively. These results showed that clinical-grade donor NK cell production from CD34+ cells is feasible.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rosenberg EB, McCoy JL, Green SS, Donnelly FC, Siwarski DF, Levine PH et al. Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst 1974; 52: 345–352.
Herberman RB, Nunn ME, Holden HT, Lavrin DH . Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230–239.
Di Santo JP . Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006; 24: 257–286.
Caligiuri MA . Human natural killer cells. Blood 2008; 112: 461–469.
Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA . Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935–1947.
Verheyden S, Demanet C . NK cell receptors and their ligands in leukemia. Leukemia 2008; 22: 249–257.
Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730–732.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.
Lundqvist A, Philip McCoy J, Samsel L, Childs R . Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007; 109: 3603–3606.
Gonzalez S, Groh V, Spies T . Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121–138.
Parham P, McQueen KL . Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003; 3: 108–122.
Martin PJ . Overview of hematopoietic cell transplantation immunology. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation,, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 16–30.
Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.
Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297.
Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351–1357.
Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073–1084.
Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690–697.
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
Lee KH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant 2009; 15: 61–72.
Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003; 31: 39–44.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W . Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414–417.
Ljunggren HG, Malmberg KJ . Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329–339.
Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835–1838.
Schulze A, Schirutschke H, Oelschlagel U, Schmitz M, Fussel M, Wassmuth R et al. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 2008; 36: 378–389.
Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641–653.
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051–3057.
Yoon SR, Chung JW, Choi I . Development of natural killer cells from hematopoietic stem cells. Mol Cells 2007; 24: 1–8.
Lee KN, Kang HS, Jeon JH, Kim EM, Yoon SR, Song H et al. VDUP1 is required for the development of natural killer cells. Immunity 2005; 22: 195–208.
Mrozek E, Anderson P, Caligiuri MA . Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996; 87: 2632–2640.
Sullivan K . Graft-vs host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 635–664.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD et al. KIR Ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828–836.
Remberger M, Sundberg B . Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005; 90: 931–938.
Poggi A, Zocchi MR . Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmun Rev 2005; 4: 532–536.
Acknowledgements
This work was supported in part by grants from the GRL project and the New Drug Target Discovery Project (M10848000352-08N4800-35210), the Ministry of Education, Science and Technology, Republic of Korea (IC and SRY).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
KHL received an honorarium for a lecture from Genzyme. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Bone Marrow Transplantation website
Rights and permissions
About this article
Cite this article
Yoon, S., Lee, Y., Yang, S. et al. Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 45, 1038–1046 (2010). https://doi.org/10.1038/bmt.2009.304
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.304
Keywords
This article is cited by
-
The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients—a randomized trial
Leukemia (2023)
-
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Gene Therapy (2021)
-
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Stem Cell Research & Therapy (2020)
-
Challenges of NK cell-based immunotherapy in the new era
Frontiers of Medicine (2018)
-
Immunotherapy after hematopoietic stem cell transplantation using umbilical cord blood-derived products
Cancer Immunology, Immunotherapy (2017)